Synergy Pharmaceuticals Company Profile (NASDAQ:SGYP)

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) posted its earnings results on Wednesday, August, 9th. The company reported ($0.33) EPS for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.08. The company had revenue of $2.31 million for the quarter, compared to the consensus estimate of $1.98 million. During the same period last year, the firm earned ($0.23) earnings per share. View Synergy Pharmaceuticals' Earnings History.

10 brokers have issued twelve-month price targets for Synergy Pharmaceuticals' shares. Their forecasts range from $2.50 to $15.00. On average, they anticipate Synergy Pharmaceuticals' stock price to reach $9.60 in the next twelve months. View Analyst Ratings for Synergy Pharmaceuticals.

Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (9/13/2017)
• 2. HC Wainwright analysts commented, "We note that the launch of Trulance appears to be progressing on multiple fronts, with the company having reached 66% of its targeted prescriber base and over 90% of the high-volume prescribers (deciles 8-10). According to QuintilesIMS data, as of mid-2017 over 12,600 Trulance prescriptions had been filled and total monthly prescription volume has increased on average over 182% month-over-month during that period. Over 32% of all high prescribers had written a Trulance prescription since the drug was launched earlier this year, with an average increase for all prescribers of approximately 140% month-over-month. Trulance achieved 6.8% new-to-brand prescription (NBRx) total market share and 12% NBRx market share among gastroenterologists. Importantly, about 55% of new Trulance prescriptions filled since launch were coming from new patients not previously on a branded prescription treatment and 45% were patients who converted from other branded prescription treatments." (8/10/2017)
• 3. Cantor Fitzgerald analysts commented, "Management upbeat about early returns. SGYP reported 2Q17 results and posted a new corporate presentation to provide an update of the Trulance launch (here). We spoke with management (no results call was held) to hear its views regarding how the launch is proceeding. Acknowledging the inherent positive bias of company managements that have launched their inaugural product, we believe metrics provided by SGYP may, however, show an objective snapshot of the launch." (8/10/2017)
• 4. BTIG Research analysts commented, "With the US launch of Trulance (3 mg plecanatide, for the treatment of chronic constipation) now officially underway, investor focus now turns to the ramp for Trulance in the US market. We continue to believe management is up to the task of successfully launching Trulance via its hybrid sales model (utilizing an experienced contract sales force of ~150 - 200 reps), which is expected to target ~27,000 high-prescribing physicians. While we believe formulary access for Trulance could take up to 6 months, we think most insurance plans will put Trulance on a Tier 3 co-pay, with the Co. offering its 'savings to go' program as an offset. Our channel checks with several local pharmacies in NYC this morning suggest that this program will enable patients to get access to Trulance at a much lower cost (no more than $25 per Rx). Management also recently highlighted at an investor conference earlier today that a nationwide sampling program is underway. In sum, we expect the launch of Trulance to lead to more patients switching from OTC laxatives to Rx treatments, with Trulance leading to an expansion of the overall Rx market." (3/21/2017)

Synergy Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 67,570,644 shares, an increase of 6.8% from the August 15th total of 63,271,755 shares. Based on an average daily volume of 2,888,418 shares, the days-to-cover ratio is currently 23.4 days. Currently, 30.1% of the company's shares are short sold.

Some companies that are related to Synergy Pharmaceuticals include Clinigen Group PLC (CLIN), Dermira (DERM), Acorda Therapeutics (ACOR), Five Prime Therapeutics (FPRX), Xencor (XNCR), NeuroDerm (NDRM), Omeros Corporation (OMER), Athenex (ATNX), Ascendis Pharma A/S (ASND), REGENXBIO (RGNX), ZIOPHARM Oncology (ZIOP), Retrophin (RTRX), Amarin Corporation PLC (AMRN), Intra-Cellular Therapies (ITCI), Keryx Biopharmaceuticals (KERX), PTC Therapeutics (PTCT), Reata Pharmaceuticals (RETA) and Aduro Biotech (ADRO).

Synergy Pharmaceuticals' management team includes the folowing people:

• Gary S. Jacob Ph.D., Chairman of the Board, President, Chief Executive Officer
• Gary G. Gemignani, Chief Financial Officer, Executive Vice President
• Marino Garcia, Executive Vice President, Chief Strategy Officer
• Patrick H. Griffin M.D., Executive Vice President, Chief Medical Officer
• Troy Hamilton, Executive Vice President, Chief Commercial Officer
• Melvin K. Spigelman M.D., Lead Independent Director
• Thomas H. Adams Jr. Ph.D., Independent Director
• John P. Brancaccio CPA, Independent Director
• Timothy S. Callahan, Independent Director
• Richard J. Daly, Independent Director

Synergy Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.75%), State Street Corp (5.75%), Northern Trust Corp (1.25%), TimesSquare Capital Management LLC (1.14%), Pictet Asset Management Ltd. (0.89%) and JPMorgan Chase & Co. (0.88%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.

Synergy Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., TIAA CREF Investment Management LLC, Palisade Capital Management LLC NJ, Bank of New York Mellon Corp, Cambridge Investment Research Advisors Inc., D.A. Davidson & CO. and State Treasurer State of Michigan. View Insider Buying and Selling for Synergy Pharmaceuticals.

Synergy Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., OxFORD Asset Management LLP, JPMorgan Chase & Co., Northern Trust Corp, Hikari Power Ltd, State Street Corp, Virtu KCG Holdings LLC and Pictet Asset Management Ltd.. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.

Shares of Synergy Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Synergy Pharmaceuticals stock can currently be purchased for approximately $2.67.